Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report

Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report

Immune checkpoint inhibitors (ICI) have been developed in gastric adenocarcinomas and approved in first-line metastatic setting (in combination with chemotherapy) as well as in pretreated patients. Microsatellite instability-high (MSI-H) tumors are predicted to derive high benefit from ICI but data...

Full description

Bibliographic Details
Main Authors: Romain Varnier, Thibaut Garrivier, Emilie Hafliger, Aymeric Favre, Clélia Coutzac, Clément Spire, Pauline Rochefort, Matthieu Sarabi, Françoise Desseigne, Pierre Guibert, Anne Cattey-Javouhey, Pamela Funk-Debleds, Charles Mastier, Adrien Buisson, David Pérol, Oliver Trédan, Jean-Yves Blay, Jean-Marc Phelip, Christelle de la Fouchardiere
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Oncology
Subjects:
gastric cancer
MSI -H
immunotherapy
hyperprogression
durvalumab
tremelimumab
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.756365/full

Similar Items

Similar Items